125 related articles for article (PubMed ID: 9704833)
1. Low-dose methotrexate in the treatment of widespread morphea.
Seyger MM; van den Hoogen FH; de Boo T; de Jong EM
J Am Acad Dermatol; 1998 Aug; 39(2 Pt 1):220-5. PubMed ID: 9704833
[TBL] [Abstract][Full Text] [Related]
2. Comparison of methotrexate with placebo in the treatment of systemic sclerosis: a 24 week randomized double-blind trial, followed by a 24 week observational trial.
van den Hoogen FH; Boerbooms AM; Swaak AJ; Rasker JJ; van Lier HJ; van de Putte LB
Br J Rheumatol; 1996 Apr; 35(4):364-72. PubMed ID: 8624641
[TBL] [Abstract][Full Text] [Related]
3. A randomized, controlled trial of methotrexate versus placebo in early diffuse scleroderma.
Pope JE; Bellamy N; Seibold JR; Baron M; Ellman M; Carette S; Smith CD; Chalmers IM; Hong P; O'Hanlon D; Kaminska E; Markland J; Sibley J; Catoggio L; Furst DE
Arthritis Rheum; 2001 Jun; 44(6):1351-8. PubMed ID: 11407694
[TBL] [Abstract][Full Text] [Related]
4. Skin scoring in systemic sclerosis: a modification--relations to subtypes and the aminoterminal propeptide of type III procollagen (PIIINP).
Zachariae H; Bjerring P; Halkier-Sørensen L; Heickendorff L; Søndergaard K
Acta Derm Venereol; 1994 Nov; 74(6):444-6. PubMed ID: 7701875
[TBL] [Abstract][Full Text] [Related]
5. Serum aminoterminal propeptide of type III procollagen in systemic sclerosis. A follow-up--investigations in subclasses and during therapy.
Heickendorff L; Parvez A; Bjerring P; Halkier-Sørensen L; Zachariae H
Acta Derm Venereol; 1991; 71(3):185-8. PubMed ID: 1678217
[TBL] [Abstract][Full Text] [Related]
6. The value of dynamic hepatic scintigraphy and serum aminoterminal propeptide of type III procollagen for early detection of methotrexate-induced hepatic damage in psoriasis patients.
vanDooren-Greebe RJ; Kuijpers AL; Buijs WC; Kniest PH; Corstens FH; Nagengast FM; de Boo T; Willems JL; Duller P; van de Kerkhof PC
Br J Dermatol; 1996 Mar; 134(3):481-7. PubMed ID: 8731673
[TBL] [Abstract][Full Text] [Related]
7. Serum type III procollagen aminopeptide for assessing liver damage in methotrexate-treated psoriatic patients.
Boffa MJ; Smith A; Chalmers RJ; Mitchell DM; Rowan B; Warnes TW; Shomaf M; Haboubi NY
Br J Dermatol; 1996 Oct; 135(4):538-44. PubMed ID: 8915142
[TBL] [Abstract][Full Text] [Related]
8. Procollagen Type I and III Aminoterminal Propeptide Levels and Severity of Interstitial Lung Disease in Mexican Women With Progressive Systemic Sclerosis.
Gonzalez-Lopez L; Rocha-Muñoz AD; Olivas-Flores EM; Garcia-Gonzalez A; Peguero-Gómez AR; Flores-Navarro J; Villa-Manzano AI; Zavaleta-Muñiz SA; Salazar-Paramo M; Mejía M; Juárez-Contreras P; Vazquez-Del Mercado M; Cardona-Muñoz EG; Trujillo-Hernández B; Nava-Zavala AH; Gamez-Nava JI
Arch Bronconeumol; 2015 Sep; 51(9):440-8. PubMed ID: 25301411
[TBL] [Abstract][Full Text] [Related]
9. The value of amino-terminal propeptide of type III procollagen in routine screening for methotrexate-induced liver fibrosis: a 10-year follow-up.
Zachariae H; Heickendorff L; Søgaard H
Br J Dermatol; 2001 Jan; 144(1):100-3. PubMed ID: 11167689
[TBL] [Abstract][Full Text] [Related]
10. Serum aminoterminal propeptide of type III procollagen in progressive systemic sclerosis and localized scleroderma.
Zachariae H; Halkier-Sørensen L; Heickendorff L
Acta Derm Venereol; 1989; 69(1):66-70. PubMed ID: 2563612
[TBL] [Abstract][Full Text] [Related]
11. Rapid and sustained improvement in bone and cartilage turnover markers with the anti-interleukin-6 receptor inhibitor tocilizumab plus methotrexate in rheumatoid arthritis patients with an inadequate response to methotrexate: results from a substudy of the multicenter double-blind, placebo-controlled trial of tocilizumab in inadequate responders to methotrexate alone.
Garnero P; Thompson E; Woodworth T; Smolen JS
Arthritis Rheum; 2010 Jan; 62(1):33-43. PubMed ID: 20039425
[TBL] [Abstract][Full Text] [Related]
12. Low effectiveness of methotrexate in the management of localised scleroderma (morphea) based on an ultrasound activity score.
Vera-Kellet C; Meza-Romero R; Moll-Manzur C; Ramírez-Cornejo C; Wortsman X
Eur J Dermatol; 2021 Dec; 31(6):813-821. PubMed ID: 35107072
[TBL] [Abstract][Full Text] [Related]
13. An open-label, dose-ranging study of methotrexate for moderate-to-severe adult atopic eczema.
Weatherhead SC; Wahie S; Reynolds NJ; Meggitt SJ
Br J Dermatol; 2007 Feb; 156(2):346-51. PubMed ID: 17223876
[TBL] [Abstract][Full Text] [Related]
14. Efficacy and safety of systemic methotrexate in two fixed doses of 10 mg or 25 mg orally once weekly in adult patients with severe plaque-type psoriasis: a prospective, randomized, double-blind, dose-ranging study.
Dogra S; Krishna V; Kanwar AJ
Clin Exp Dermatol; 2012 Oct; 37(7):729-34. PubMed ID: 22830389
[TBL] [Abstract][Full Text] [Related]
15. Methotrexate-induced liver cirrhosis. Clinical, histological and serological studies--a further 10-year follow-up.
Zachariae H; Søgaard H; Heickendorff L
Dermatology; 1996; 192(4):343-6. PubMed ID: 8864370
[TBL] [Abstract][Full Text] [Related]
16. Interferon-alpha does not improve outcome at one year in patients with diffuse cutaneous scleroderma: results of a randomized, double-blind, placebo-controlled trial.
Black CM; Silman AJ; Herrick AI; Denton CP; Wilson H; Newman J; Pompon L; Shi-Wen X
Arthritis Rheum; 1999 Feb; 42(2):299-305. PubMed ID: 10025924
[TBL] [Abstract][Full Text] [Related]
17. Monitoring patients on methotrexate: hepatic fibrosis not seen in patients with normal serum assays of aminoterminal peptide of type III procollagen.
Maurice PD; Maddox AJ; Green CA; Tatnall F; Schofield JK; Stott DJ
Br J Dermatol; 2005 Mar; 152(3):451-8. PubMed ID: 15787813
[TBL] [Abstract][Full Text] [Related]
18. Type III procollagen N-terminal propeptide, soluble interleukin-2 receptor, and von Willebrand factor in systemic sclerosis.
Lee YJ; Shin KC; Kang SW; Lee EB; Kim HA; Song YW
Clin Exp Rheumatol; 2001; 19(1):69-74. PubMed ID: 11247328
[TBL] [Abstract][Full Text] [Related]
19. Long-term therapy with plasma exchange in systemic sclerosis: effects on laboratory markers reflecting disease activity.
Cozzi F; Marson P; Rosada M; De Silvestro G; Bullo A; Punzi L; Todesco S
Transfus Apher Sci; 2001 Aug; 25(1):25-31. PubMed ID: 11791759
[TBL] [Abstract][Full Text] [Related]
20. The use of serologic markers for collagen synthesis and degradation in systemic sclerosis.
Heickendorff L; Zachariae H; Bjerring P; Halkier-Sørensen L; Søndergaard K
J Am Acad Dermatol; 1995 Apr; 32(4):584-8. PubMed ID: 7896946
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]